Table 3. Semiquantitative analysis of CXCR6 and CXCL16 immunoreactivity in tissue specimen of patients with primary urothelial cancer (UC; n=13 low grade, n=4 high grade) or an inflammation of the bladder (Uro).
| Immunoreactivity | CXCL16 | CXCR6 | ||
|---|---|---|---|---|
| Across the whole slide (Method 1) | UC (n=17) | Uro (n=15) | UC (n=17) | Uro (n=15) |
| Absent, n | 3 (18%) | 0 (0%) | 0 (0 %) | 0 (0%) |
| Weak, n | 13 (76%) | 2 (13%) | 2 (12%) | 0 (0%) |
| Intermediate, n | 1 (6%) | 10 (67%) | 7 (41%) | 5 (33%) |
| Strong, n | 0 (0%) | 3 (20%) | 8 (47%) | 10 (67%) |
| Percentage of stained area (Method 2) | Mean | Mean | Mean | Mean |
| Absent | 12.3% | 0% | 0% | 0.7% |
| Weak | 48.8% | 16.7% | 0% | 6.6% |
| Intermediate | 27.7% | 28.5% | 29.6% | 10.5% |
| Strong | 11.1% | 55.9 % | 70.4% | 82.2% |
| H-Scoring (Method 3) | Mean ± SD | Mean ± SD | ||
| 137.65±72.92 | 237.93±62.59* | 270.37±27.45 | 283.44±34.62 | |
n, number of samples; Mean±standard deviation H-scores in UC and patients with an inflammation of the bladder; *p=0.0016 p-value from Mann-Whitney test.